Connection

NATHAN FOWLER to Administration, Oral

This is a "connection" page, showing publications NATHAN FOWLER has written about Administration, Oral.
Connection Strength

0.133
  1. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013 Jan 01; 31(1):88-94.
    View in: PubMed
    Score: 0.078
  2. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
    View in: PubMed
    Score: 0.031
  3. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9.
    View in: PubMed
    Score: 0.020
  4. Quinidine for prophylaxis of arrhythmias in acute myocardial infarction. N Engl J Med. 1971 Oct 28; 285(18):979-86.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.